InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
TB Alliance to leverage AlphaMeld®, an AI-powered platform to capture and accelerate innovation to address unmet needs GUILFORD, Conn., June 02, 2020 […]
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
TB Alliance to leverage AlphaMeld®, an AI-powered platform to capture and accelerate innovation to address unmet needs GUILFORD, Conn., June 02, 2020 […]
InveniAI Introduces New Products to its AI-Powered Pharmaceutical Drug Discovery and Development Suite
TargetMeld™ and RxMeld™ to provide predictive analytics and comprehensive access to emerging targets and clinical assets with a quantified probability of success […]
InveniAI Launches Suite of Products Powered by AlphaMeld® an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences
InveniAI Launches Suite of Products Powered by AlphaMeld® an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life […]
InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU
Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology expertise to a world-class board of directors at InveniAI. InveniAI […]
Microsoft Features InveniAI in their Series, Now This Future: “AI for Change”
Spotlight on how artificial intelligence and machine learning is transforming pharmaceutical R&D innovation GUILFORD, CT., March 26, 2019 — InveniAI® Corporation, a global […]
InveniAI Featured in The Guardian’s Rare Disease Campaign
InveniAI Featured in The Guardian’s Rare Disease Campaign to Showcase how Artificial Intelligence can be Leveraged to Create Patient Solutions Artificial intelligence […]
InveniAI Enters Strategic Artificial Intelligence Collaboration with Kyowa Hakko Kirin
Focus on leveraging the power of AI to expand the therapeutic index of existing portfolio BRANFORD, CT December 11, 2018, InveniAI® Corporation, […]